Proliferative index in phaeochromocytomas: Does it predict the occurrence of metastases?

Journal of Pathology

Volumn 191, Issue 2, 2000, Pages 175-180

  Van Der Harst, Erwin ^a   Bruining, Hajo A ^a   Bonjer, H Jaap ^a   Van Der Ham, Frieda ^a   Dinjens, Winand N ^a   Lamberts, Steven W J ^a   De Herder, Wouter W ^a   Koper, Jan W ^a   Stijnen, Theo ^a   Proye, Charles ^b   Lecomte Houcke, Martine ^b   Bosman, Fred T ^c   De Krijger, Ronald R ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Malignancy; Metastases; MIB 1; Phaeochromocytoma; Prognosis; S100; Surgery

Indexed keywords

ARTICLE; CANCER GRADING; CELL PROLIFERATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALIGNANT TRANSFORMATION; METASTASIS POTENTIAL; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROGNOSIS; TARGET CELL; TUMOR LOCALIZATION; TUMOR VOLUME;

ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; AGED; CELL COUNT; CELL CYCLE PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; NECROSIS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PHEOCHROMOCYTOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REGRESSION ANALYSIS;

EID: 0034040882     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(200006)191:2<175::AID-PATH615>3.0.CO;2-Z     Document Type: Article

References (31)

1. Medeiros LJ, Wolf BC, Balogh K, Federman M. Adrenal phaeochromocytoma: a clinicopathologic review of 60 cases. Hum Pathol 1985; 16: 580-589.
2. Scott HW, Halter SA. Oncologic aspects of phaeochromocytoma: the importance of follow-up. Surgery 1984; 96: 1061-1066.
3. Schlumberger M, Gicquel C, Lumbroso J, et al. Malignant phaeochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. J Endocrinol Invest 1992; 15: 631-642.
4. Mornex R, Berthezene F, Peyrin L, Tran Minh V, Martin JP, Fulchiron D. Phaeochromocytomes malins. Arch Mal Coeur 1979; 72: 96-102.
5. Linnoila RI, Keiser HR, Steinberg SM, Lack EE. Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol 1990; 21: 1168-1180.
6. DeLellis RA. Does the evaluation of proliferative activity predict malignancy or prognosis in endocrine tumours? Hum Pathol 1995; 26: 131-134.
7. Hitchcock CL. Ki-67 staining as a means to simplify analysis of tumour cell proliferation. Am J Clin Pathol 1991; 96: 444-446.
8. Clarke MR, Weynant RJ, Watson GC, Carty SE. Prognostic markers in phaeochromocytoma. Hum Pathol 1998; 28: 522-526.
9. Kimura N, Miura W, Noshiro T, Miura Y, Ookuma T, Nagura H. Ki-67 is an indicator of progression of neuroendocrine tumours. Endocr Pathol 1994; 5: 223-228.
10. Wintzer HO, Zipfel I, Schulte-Monting J, Hellerich U, von Kleist S. Ki-67 immunostaining in human breast carcinoma and its relationship to prognosis. Cancer 1991; 67: 421-429.
11. Unger P, Hoffman K, Pertsemlidis D, Thung S, Wolfe D, Kaneko M. S100 protein-positive sustentacular cells in malignant and locally aggressive adrenal phaeochromocytomas. Arch Pathol Lab Med 1991; 115: 484-487.
12. Pommier RF, Vetto JT, Billingsly K, Woltering EA, Brennan MF. Comparison of adrenal and extraadrenal phaeochromocytomas. Surgery 1993; 114: 1160-1165.
13. Mornex R, Badet C, Peyrin L. Malignant phaeochromocytoma: a series of 14 cases observed between 1966 and 1990. J Endocrinol Invest 1992; 15: 643-649.
14. John H, Ziegler WH, Hauri D, Jaeger P. Phaeochromocytomas: can malignant potential be predicted? Urology 1999; 53: 679-683.
15. Plouin P-F, Chatellier G, Fofol I, Corvol P. Tumour recurrence and hypertension persistence after successful phaeochromocytoma operation. Hypertension 1997; 29: 1133-1139.
16. Donhuijsen K, Schmidt U, Hirche H. Mitosis counts: reproducibility and significance in grading malignancy. Hum Pathol 1986; 17: 1122-1125.
17. Rudolph P, Peters J, Lorenz D, Schmidt D, Parwaresch R. Correlation between mitotic and Ki-67 labelling indices in paraffin-embedded carcinoma specimens. Hum Pathol 1998; 29: 1216-1222.
18. Abbona GC, Papotti M, Gasparri G, Bussolati G. Proliferative index in parathyroid tumours as detected by Ki-67 immunostaining. Hum Pathol 1995; 26: 135-138.
19. Katoh R, Bray CE, Suzuki K, et al. Growth activity in hyperplastic and neoplastic human thyroid determined by an immunohistochemical staining procedure using monoclonal antibody MIB-1. Hum Pathol 1995; 26: 139-146.
20. Achilles E, Padberg BC, Holl K, Kloppel G, Schroder S. Immunocytochemistry of paragangliomas value of staining for S-100 protein and glial fibrillary acid protein in diagnosis and prognosis. Histopathology 1991; 18: 453-458.
21. Montresor E, Iacono C, Nifosi F, et al. Retroperitoneal paragangliomas: role of immunohistochemistry in the diagnosis of malignancy and in assessment of prognosis. Eur J Surg 1994; 160: 547-552.
22. Shapiro B, Sisson JC, Lloyd R, Nakajo M, Satterlec W, Beierwaltes WH. Malignant phaeochromocytoma: clinical, biochemical and scintigraphic characterisation. Clin Endocrinol (Oxford) 1984; 20: 189-203.
23. Hoffman K, Gil J, Barba J, et al. Morphometric analysis of benign and malignant adrenal phaeochromocytomas. Arch Pathol Lab Med 1993; 117: 244-247.
24. Grouzmann E, Gicquel C, Plouin PF, Schlumberger M, Comoy E, Bohuon C. Neuropeptide Y and neuron-specific enolase levels in benign and malignant phaeochromocytomas. Cancer 1990; 66: 1833-1835.
25. Helman LJ, Cohen PS, Averbuch SD, Cooper MJ, Keiser HR, Israel MA. Neuropeptide Y expression distinguishes malignant from benign phaeochromocytoma. J Clin Oncol 1989; 7: 1720-1725.
26. Proye C, Vix M, Goropoulos A, Kerlo P, Lecomte Houcke M. High incidence of malignant phaeochromocytoma in a surgical unit. 26 cases of 100 patients operated from 1971 to 1991. J Endocrinol Invest 1992; 15: 651-663.
27. Nativ O, Grant CS, Sheps SG, et al. The clinical significance of nuclear DNA ploidy pattern in 184 patients with phaeochromocytoma. Cancer 1992; 69: 2683-2687.
28. Heaney HP, O'Rourke D, Arthur K, et al. Flow cytometric analysis does not reliably differentiate benign from malignant phaeochromocytoma. Clin Endocrinol 1996; 44: 233-238.
29. Padberg BC, Garbe E, Achilles E, Dralle H, Bressel M, Schroder S. Adrenomedullary hyperplasia and phaeochromocytoma. DNA cytophotometric findings in 47 cases. Virchows Arch A [Pathol Anat Histopathol] 1990; 416: 443-446.
30. De Krijger RR, van der Harst E, van der Ham F, et al. Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas. J Pathol 1999; 188: 51-55.
31. van der Harst E, De Krijger RR, Bruining HA, et al. Prognostic-value of RET proto-oncogene mutations in malignant and benign, sporadic phaeochromocytomas. Int J Cancer 1998; 79: 537-540.